ENDPOINTS NEWS28m
Lon­za ex­pands bio­con­ju­gates fac­to­ry; WuXi Bio adds ca­pac­i­ty in Ger­many
Lonza, WuXi Biologics, and Baxter Healthcare announce facility expansions and updates. Repligen reports revenue growth, while ...
ENDPOINTS NEWS40m
New Zealand clears first clin­i­cal tri­al of epi­ge­net­ic edit­ing for he­pati­tis B
New Zealand approved Tune Therapeutics' TUNE-401, an epigenetic editing therapy for chronic hepatitis B, for human trials.
ENDPOINTS NEWS46m
No­vo Nordisk to phase out its pro­duc­tion of hu­man in­sulin pens glob­al­ly
No­vo Nordisk said Thurs­day that it plans to even­tu­al­ly halt all of its hu­man in­sulin pen pro­duc­tion glob­al­ly, ...
ENDPOINTS NEWS55m
Zai Lab aims to raise $200M; Kro­nos Bio to seek ‘strate­gic’ op­tions
Zai Lab announces $200M share offering amid 47% revenue growth and plans for KarXT submission in China. Multiple companies report changes: Kronos Bio seeks alternatives, Allogene halts trial ...